Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Radboud J Duintjer Tebbens

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Vaccine|June 14, 2017
Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelersRadboud J Duintjer Tebbens, Kimberly M Thompson
BMC Infectious Diseases|September 19, 2015
The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmissionKimberly M Thompson, Radboud J Duintjer Tebbens
Medscape Journal of Medicine|October 18, 2008
The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessationKimberly M Thompson, Radboud J Duintjer Tebbens
Risk Analysis : an Official Publication of the Society for Risk Analysis|August 12, 2014
Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting ExamplesKimberly M Thompson, Radboud J Duintjer Tebbens
BMC Infectious Diseases|September 19, 2015
Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypesKimberly M Thompson, Radboud J Duintjer Tebbens
Lancet (London, England)|April 24, 2007
Eradication versus control for poliomyelitis: an economic analysisKimberly M Thompson, Radboud J Duintjer Tebbens
Expert Review of Vaccines|July 31, 2018
Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccineRadboud J Duintjer Tebbens, Kimberly M Thompson
Expert Review of Vaccines|April 25, 2017
Poliovirus vaccination during the endgame: insights from integrated modelingRadboud J Duintjer Tebbens, Kimberly M Thompson
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 23, 2006
Retrospective cost-effectiveness analyses for polio vaccination in the United StatesKimberly M Thompson, Radboud J Duintjer Tebbens
Expert Review of Vaccines|December 7, 2013
National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradicationKimberly M Thompson, Radboud J Duintjer Tebbens
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Vaccine|June 14, 2017
Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelersRadboud J Duintjer Tebbens, Kimberly M Thompson
BMC Infectious Diseases|September 19, 2015
The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmissionKimberly M Thompson, Radboud J Duintjer Tebbens
Medscape Journal of Medicine|October 18, 2008
The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessationKimberly M Thompson, Radboud J Duintjer Tebbens
Risk Analysis : an Official Publication of the Society for Risk Analysis|August 12, 2014
Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting ExamplesKimberly M Thompson, Radboud J Duintjer Tebbens
BMC Infectious Diseases|September 19, 2015
Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypesKimberly M Thompson, Radboud J Duintjer Tebbens
Lancet (London, England)|April 24, 2007
Eradication versus control for poliomyelitis: an economic analysisKimberly M Thompson, Radboud J Duintjer Tebbens
Expert Review of Vaccines|July 31, 2018
Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccineRadboud J Duintjer Tebbens, Kimberly M Thompson
Expert Review of Vaccines|April 25, 2017
Poliovirus vaccination during the endgame: insights from integrated modelingRadboud J Duintjer Tebbens, Kimberly M Thompson
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 23, 2006
Retrospective cost-effectiveness analyses for polio vaccination in the United StatesKimberly M Thompson, Radboud J Duintjer Tebbens
Expert Review of Vaccines|December 7, 2013
National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradicationKimberly M Thompson, Radboud J Duintjer Tebbens
Pageof 7